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Melanoma is an invasive malignancy with a high fre-
quency of blood-borne metastases, but circulating
tumor cells (CTCs) have not been readily isolated.
We adapted microfluidic CTC capture to a tamox-
ifen-driven B-RAF/PTEN mouse melanoma model.
CTCs were detected in all tumor-bearing mice and
rapidly declined after B-RAF inhibitor treatment.
CTCs were shed early from localized tumors, and a
short course of B-RAF inhibition following surgical
resection was sufficient to dramatically suppress
distant metastases. The large number of CTCs in
melanoma-bearing mice enabled a comparison of
RNA-sequencing profiles with matched primary tu-
mors. A mouse melanoma CTC-derived signature
correlated with invasiveness and cellular motility in
human melanoma. CTCs were detected in smaller
numbers in patients with metastatic melanoma and
declined with successful B-RAF-targeted therapy.
Together, the capture and molecular characteriza-
tion of CTCs provide insight into the hematogenous
spread of melanoma.
INTRODUCTION
Recent advances in the treatment of metastatic melanoma have
altered the outlook in this previously refractory cancer. In pa-
tients with metastatic B-RAF mutant melanoma, dramatic (albeit
transient) responses to B-RAF-MAPK blockade require timely
monitoring of drug response so that treatment options can be
adjusted (Flaherty et al., 2012). The identification of effective
treatments for metastatic disease suggests that these drugsmay be applied even more successfully in patients in earlier
stages of disease, such as stage II or III, where microscopic
distant metastases may be eradicated by targeted therapies
(Balch et al., 2009). However, identifying high-risk patients who
should receive such postoperative ‘‘adjuvant’’ therapy is chal-
lenging using the current clinical staging, and would benefit
from more reliable indicators of tumor invasiveness and recur-
rence risk. For patients with advanced melanoma, as well as
those with localized disease, analysis of circulating tumor cells
(CTCs) may therefore provide a novel biomarker to guide thera-
peutic decisions.
In addition to diagnostic applications, the detailed molecular
characterization of melanoma cells circulating in the blood-
stream may yield new insights into the process of melanoma
metastasis (Liu et al., 2011; Ramsko¨ld et al., 2012). However,
there are significant challenges. CTCs are rare even in patients
with advanced cancer. Moreover, melanomas do not express
the classical epithelial cell surface marker EpCAM, which has
formed the basis for most CTC isolation strategies (Yu et al.,
2011). Some melanoma-specific cell surface epitopes have
been proposed for CTC enrichment (Khoja et al., 2013), and
the large size of tumor cells within primary melanomas has led
to the application of filtering strategies to isolate melanoma
CTCs (De Giorgi et al., 2010), although recent studies have sug-
gested that melanoma CTCs may span a wide range of cell sizes
(Ozkumur et al., 2013). Given the difficulty of isolating whole mel-
anoma CTCs, RT-PCR-based measurements of blood-derived,
melanoma-specific transcripts have also been employed. In pa-
tients with locally invasive tumors, positive PCR signals in such
assays are associated with a poor prognosis and an increased
risk of distant metastasis (Hoshimoto et al., 2012). Taken
together, multiple approaches suggest the presence of mela-
noma cells in the bloodstream of patients in various stages of
disease, but a robust cell-capture platform is essential for effi-
cient detection and molecular characterization of these cells.Cell Reports 7, 645–653, May 8, 2014 ª2014 The Authors 645
Figure 1. Identification of CTCs in the B-rafCA/+/Ptenflox/flox Mouse Melanoma Model
(A) Representative images of melanoma induced by focal tamoxifen injection. Arrowheads show tumor progression at the injection site from day 7 to day 24 (left)
and cutaneous metastasis at day 56 after tumor induction (right).
(B) Upper: representative image of a mouse melanoma CTC adjacent to a leukocyte. Lower: a cluster of four CTCs. Blue, DAPI; green, CD45; red, S100. Scale
bars, 10 mm.
(C) Quantification of CTCs from a cohort of tumor-bearingmice (green, n = 12) and control mice (red, genotype-matched tumor-freemice, n = 8; blue, Tyr-CreER
mice that received tamoxifen injection, n = 5; open circles, syngeneic C57BL/6 mice, n = 9). Solid lines, median CTC counts; dashed line, threshold ofR14 S100+
cells/ ml.
(D and E) Concordant changes in (D) tumor volume and (E) CTCs in tumor-bearing mice fed with control chow or PLX4720-containing chow (blue, PLX4720; red,
control). Mean value, error bars represent SD.
See also Figure S1.Here, we adapted a microfluidic platform, the HBCTC-Chip
(Stott et al., 2010), to capture melanoma CTCs using panels
of antibodies against melanoma-specific cell surface markers,
followed by immunofluorescence (IF) staining for melanoma
antigens and optimized on-chip imaging. We applied this
HBCTC-Chip to a robust, inducible B-RAF-PTEN-driven mouse
melanoma model (Dankort et al., 2009), in which we validated
capture of bona fide melanoma CTCs and monitored their
response to targeted therapy and the timing of CTC generation
by localized lesions. The large number of CTCs generated in
the mouse melanoma model, together with the consistent ge-
netic background, allowed us to compare RNA sequencing
(RNA-seq) profiles of matched primary tumors, metastatic
lesions, and CTCs, thereby generating a melanoma CTC signa-
ture that identified high-risk subsets in human melanoma-
derived specimens. Based on its validation in the mouse
model, we applied the melanoma HBCTC-Chip to a pilot cohort
of human samples.646 Cell Reports 7, 645–653, May 8, 2014 ª2014 The AuthorsRESULTS
Microfluidic Isolation of CTCs and Their Response to
B-RAF-Targeted Therapy in a Mouse Melanoma Model
Given the considerable heterogeneity of human melanoma, we
sought to adapt the HBCTC-Chip to capture cells from a geneti-
cally engineered mouse model of melanoma (Dankort et al.,
2009). In this model, subcutaneous injection of tamoxifen at
the flank of the animal leads to activation of oncogenic B-
RAFV600E coincidently with deletion of PTENwithin melanocytes.
Melanomas are formed at the injection site with 100% pene-
trance within 3 weeks, with distant cutaneous metastases
appearing at 6–7 weeks (Figure 1A). After testing B-RAF/PTEN-
driven mouse tumors for expression of multiple lineage-specific
markers, we selected antibodies against the cell surface epi-
topes CSPG4 andMCAM for CTC capture, and antibody against
the melanoma marker S100 for staining and imaging of captured
CTCs (Figures S1A–S1D). We collected blood specimens from
Figure 2. Distant Metastasis Is Associated with the Presence of CTCs and Is Prevented by Adjuvant B-RAF Inhibition
(A) Tumor progression on 4-HT-treated ears.
(B) CTCs can be detected as early as day 7 after tumor induction and correspond to tumor progression.
(C) CTC counts correlate with tumor thickness when thickness is >0.1 mm (n = 12, R2 = 0.66).
(D) Left: schematic diagram of the experimental procedures. Right: postsurgical administration of B-RAF inhibitor delays or prevents distant metastasis. After the
affected ears were removed, the mice were fed with PLX4720-containing chow (n = 17) or control chow (n = 16) for 4 weeks. Subcutaneous metastases were
observed in the control group (10 out of 16), but not in the PLX4720-fed group (0 out of 17). Tumors on the contralateral ear were also largely suppressed by
PLX4720.
See also Figure S2 and Table S1.tumor-bearing mice (Yu et al., 2012) and processed the blood by
passing it through anti-CSPG4 and anti-MCAM functionalized
HBCTC-Chips.
Captured cells were stained for S100, and the common leuko-
cyte markers CD45 and CTCs were defined as S100+/CD45
(Figure 1B). As is done for all fluorescence-based CTC imaging,
we set a baseline for positive scoring using tumor-free controls
(Yu et al., 2012). Under the established imaging conditions, ame-
dian of two S100+/CD45 cells/ml of blood (mean 3, range 0–13
cells/ml) was observed in nontumor-bearing mice (Tyr-CreER+
mice without tamoxifen treatment, n = 8; Tyr-CreER mice
with tamoxifen injection, n = 5; syngeneic C57BL/6 mice,
n = 9). All of 12 melanoma-bearing mice (100%) scored positive
for CTCs using a threshold ofR14 S100+/CD45 cells/ml, with a
median of 114 cells/ml (mean 232, range 48–1,015 cells/ml)
(Figure 1C). The CTCs were significantly larger than leukocytes
(median size 14 mm, range 13–18 mm), and CTC clusters of two
to four cells were also recovered (Figure 1B) as reported in other
cancer types (Stott et al., 2010).
The CTC count rose progressively with increasing tumor
burden following tumor induction (Figure S1E). Oral administra-
tion of the selective B-RAF inhibitor PLX4720 resulted in aconcordant reduction in both the size of the primary tumor and
the number of CTCs. A >50% drop in CTC numbers was evident
as early as 4 days after initiation of PLX4720 therapy, and these
numbers continued to decline progressively over the 14-day
treatment period (Figures 1D, 1E, and S1F–S1H).
Prevention of Metastases from Early Melanomas by
Postresection Administration of B-RAF Inhibitor
The efficient generation and capture of CTCs in a mouse mela-
noma model, coupled with our ability to monitor the earliest
stages of tumor formation in the skin, made it possible to test
the timeline of CTC generation and seek histopathological corre-
lates within the primary tumor. For these experiments, we chose
to apply minute amounts of the active tamoxifen metabolite 4-
hydroxytamoxifen (4-HT) topically to the outer ear, thus avoiding
skin trauma associated with subcutaneous injection and gener-
ating a small initial lesion amenable to detailed histopathological
analysis. A darkening of the outer ear consistent withmelanocyte
proliferation was grossly evident 17–21 days after topical
application of 4-HT (Figure 2A), and increasing CTC numbers
were detectable in the circulation as early as 7 days (Figure 2B).
Histopathological features analyzed in the primary melanomaCell Reports 7, 645–653, May 8, 2014 ª2014 The Authors 647
(legend on next page)
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lesions included tumor thickness, tumor ulceration, tumor cell
mitoses, and fat invasion (Table S1). Consistent with well-estab-
lished predictors of clinical outcome (Carrillo et al., 2002), the
thickness of the primary lesion was most highly correlated with
increasing generation of CTCs (Figure 2C).
Initiation of melanoma in the mouse ear was followed by its
appearance in the contralateral ear at 4 weeks and disseminated
cutaneous spread (to the torso) at 7–8 weeks. We could not
determine whether the early contralateral ear involvement repre-
sented true blood-borne metastasis with a predilection for the
ear or, more likely, the effect of mouse grooming, which could
spread the 4-HT by contact to the contralateral ear. Consistent
with the rapid generation of CTCs in the mouse ear model,
resection of the primary tumor as early as 4 days following 4-
HT application did not prevent the subsequent development of
distant metastases (Figures 2D and S2). As a potential model
for the adjuvant treatment of early-stage melanoma, we tested
whether resection of the primary tumor followed by a short
course of B-RAF inhibition could delay or prevent the develop-
ment of metastases. Of 16 mice treated with 4-HT followed
by resection of the treated ear at day 4, ten (63%) developed
distant cutaneous metastases at 2 months. Remarkably, none
of 17 mice (0%) that received 4 weeks of postsurgical B-RAF in-
hibitor developed cutaneous metastases at 2 months (p < 0.001;
Figure 2D). The appearance of tumors in the contralateral ear
was significantly reduced, but not completely abrogated, by
PLX4720 treatment. When compared with the time-limited effi-
cacy of B-RAF inhibition in the setting of metastatic melanoma,
these observations suggest that a brief treatment with B-RAF
inhibitor in the postsurgical ‘‘adjuvant’’ setting, when tumor
burden is low, may have a dramatic impact on the risk of tumor
recurrence.
RNA-Seq Profile of Mouse Melanoma CTCs
The availability of matched primary melanoma, CTCs, and met-
astatic deposits in a genetically defined mouse model allowed
us to compare expression profiles for these sequential stages
of cancer dissemination. As previously described (Yu et al.,
2012), we applied single-molecule, next-generation RNA-seq
(Heliscope SingleMolecule Sequencer) to avoid the loss of signalFigure 3. Digital Gene-Expression Analysis of Mouse CTCs
(A) Schematic diagram of the digital gene expression (DGE) experiment. RNA w
tumors, and subjected to Helicos DGE analysis.
(B) Unsupervised clustering of transcripts enriched in CTCs and primary and m
expression profiles of the CTCs are distinct from those of the primary and metas
(C) Genes upregulated in a CTC-enriched population compared with mock IgG-
samples BP-55 and BP-73, respectively, with an overlap of 200 genes (right, CT
(D) Of the 200 overlapping genes in (C), 132 were specifically overexpressed in CT
compared with the metastasis (middle); of these, 118 genes were common to bo
(E) GSEA on the 132CTC-specific genes identified a number of gene sets related to
red) to low (right, light red); black vertical lines, overlap of the 132 genes with kno
2005); Hoshida liver, Hoshida liver carcinoma genes (Hoshida et al., 2009); Delys t
Schuetz ductal invasive breast cancer genes (Schuetz et al., 2006); Onken mela
melanoma, Alonso metastatic melanoma genes (Alonso et al., 2007).
(F) The signature of the 132 CTC-specific genes is associated with increased mo
(G) The signature also shows a progressive increase from benign or atypical nev
nevus; in situ, melanoma in situ; Vertical, melanoma vertical growth phase; M
metastatic melanoma short-term culture (Smith et al., 2005).
See also Figure S3 and Tables S2 and S3.associated with PCR amplification of low-quantity, heteroge-
neous templates. The median purity of CTCs enriched
by HBCTC-Chip from tumor-bearing mice was 0.3% (range
0.073%–3.85%, n = 12; Figure 1C), with higher purity achieved
from mice with higher tumor burdens. We therefore selected
another five mice with multiple metastatic lesions, obtained
CTC-enriched populations, and subjected them to microfluidic
in-line extraction of nucleic acids followed by RNA-seq. To allow
digital subtraction of contaminating leukocyte transcripts from
the CTC-enriched reads, each mouse-derived blood specimen
was processed through paired HBCTC-Chips. One HBCTC-Chip
was functionalized with antibodies to CSPG4 and MCAM
(Capture-HBCTC-Chip), and the other was mock functionalized
with matching IgG (Control-IgG-Chip), which enabled us to
achieve a more specific digital expression pattern for melanoma
CTCs. We also processed primary and metastatic melanoma
deposits using the same single-molecule sequencing platform
(Figure 3A). Although expression differences between matched
primary and metastatic tumors were evident, none of these dif-
ferences were shared across the four pairs that were success-
fully sequenced (Figure S3). Therefore, we did not identify
consistent metastasis-specific transcripts in this mouse model.
Of five mice analyzed, two (BP-55 and BP-73) had CTC-
derived RNA of sufficient quality to generate data for detailed
digital gene-expression profiling. Unsupervised clustering of
the 1,000 genes with the highest SD suggested that the CTCs
express a set of transcripts that are underrepresented in both
primary and metastatic tumors (Figure 3B). Mice BP-55 and
BP-73 respectively had 1,055 and 275 transcripts that were
overexpressed (false discovery rate [FDR] < 1 3 1005 and >2-
fold) in CTC-enriched cells compared with mock-enriched con-
trols, and 200 of these transcripts were shared between the
two specimens (CTC-common; Figure 3C). Gene Ontology anal-
ysis applied to the 200 genes identified melanosome-associated
genes (Table S2), reflecting the CTCs’ melanocytic origin. Of
these 200 CTC-common transcripts, 132 were specifically over-
expressed in CTCs compared with the primary tumor reads
(CTC-specific), 125 were overexpressed compared with meta-
static tumor reads, and 118 were common to both gene sets
(Figure 3D).as extracted from Chip-enriched cells and matched primary and metastatic
etastatic tumors from two mice (BP-55 and BP-73), demonstrating that the
tatic tumors.
enriched cells. There were 1,055 (left) and 275 (middle) upregulated genes in
C-common).
Cs compared with the primary tumor (left) and 125were overexpressed in CTCs
th gene sets (right).
cancer. Red bar, the 132 genes ranked by expression level from high (left, dark
wn gene sets. Poola breast, Poola invasive breast cancer genes (Poola et al.,
hyroid, Delys papillary thyroid cancer genes (Delys et al., 2007); Schuetz breast,
noma, Onken aggressive uveal melanoma genes (Onken et al., 2006); Alonso
tility in melanoma cell lines (Jeffs et al., 2009).
us to primary and metastatic lesions. Benign, benign nevus; Atypica, atypical
et, metastatic melanoma; Lymph, melanoma lymph node metastasis; Cult.,
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Gene set enrichment analysis (GSEA) applied to the 132 CTC-
specific genes that were upregulated in CTCs versus primary
tumors identified a signature that was previously implicated in
noncanonical WNT, TGF-b, and BMP signaling (Hoshida et al.,
2009; Figures 3E and S3C–S3F), as well as other gene sets impli-
cated in tumor invasiveness in both melanomas and breast can-
cers (Onken et al., 2006; Poola et al., 2005; Schuetz et al., 2006).
Also identified were gene sets driven by hyperactivation of the
B-RAFV600E-MAPK pathway in papillary thyroid cancer (Delys
et al., 2007) and epithelial-to-mesenchymal transition (EMT)
(Alonso et al., 2007) (Figure 3E).
We applied the mouse melanoma CTC-derived 132 metagene
signature to expression data sets of human melanoma speci-
mens, and the signature readily identified melanoma cell lines
that were ranked as having a high cell motility score (Jeffs et al.,
2009; Figure 3F). It also showed progressively increased expres-
sion in melanocytic lesions, ranging from benign or atypical nevi
to primary and metastatic melanomas (Smith et al., 2005; Fig-
ure 3G). Thus, a set of transcripts that are upregulated during
CTC generation in a mouse melanoma model may represent
pathways that denote invasive properties in human melanoma.
Microfluidic Isolation of CTCs from Patients with
Metastatic Melanoma
Our successful isolation of mouse melanoma CTCs raised the
possibility that we could capture such cells from patient-derived
blood specimens. Due to the highly heterogeneous expression
of lineage markers in human melanomas (Herlyn and Koprowski,
1988), we screened 11 human melanoma cell lines for expres-
sion of 42melanoma antigens (Figure S4).We selected a cocktail
of 12 antibodies against melanoma cell surface epitopes that
identified all 11 melanoma cell lines but reacted minimally to
normal blood cells, demonstrating capture of >90% melanoma
cells (Figure S4). A second cocktail of four distinct antibodies
against melanoma epitopes was chosen to stain captured cells
(melanoma stain [MEL], Figures 4A and S4; Table S4). As for
the mouse CTCs, we set an imaging threshold using blood spec-
imens from healthy donors. A median of 1 MEL+/CD45 cell/
2.5 ml blood was observed in control specimens (range 0–2
cells/2.5 ml; n = 10), which led us to define R3 cells/2.5 ml as
a positive CTC score. CTCs above this threshold were observed
in 138 of 174 samples (79%) from 41 patients at various stages of
treatment (median 8 cells/2.5 ml, range 0–132). Significantly
higher numbers of CTCs (p < 0.0001) were identified from
pretreatment samples (median 24 CTCs/2.5 ml, range 11–132;
n = 21; Figure 4B). Captured melanoma CTCs exhibited a wide
range of cell sizes (11–19 mm diameter) and CTC clusters (R2
cells) were identified in three out of 174 samples (Figure S5F).
Although the relatively low purity of human CTCs captured using
this assay (median 0.07%, range 0%–0.77%) precluded the
molecular analysis performed in the mouse model, it allowed
us to monitor patients undergoing therapeutic interventions. In
four patients with metastatic B-RAFV600E melanoma who were
receiving targeted anti-B-RAF therapies (two experiencing rela-
tively durable responses [patients M1 and M2] and two having
only transient benefit [patients M3 and M4]), CTC numbers
were generally correlated with clinical evaluation of disease
status (Figure 4C).650 Cell Reports 7, 645–653, May 8, 2014 ª2014 The AuthorsDISCUSSION
We have demonstrated the successful adaptation of a microflui-
dic device for melanoma CTC enrichment and applied it to a
mouse model that recapitulates the biology of B-RAF-driven
melanoma. The characterization of melanoma CTCs isolated in
this model provides an initial insight into their invasive properties
and sets the stage for potential future clinical applications. The
mouse B-RAF/PTEN-driven melanoma model demonstrates a
rise in CTC numbers as the primary tumor enlarges and metas-
tases appear. Similarly, a brisk decline in CTCs concomitant
with tumor shrinkage in response to targeted therapy is evident.
Thus, in this genetically homogeneous model, CTC numbers are
well correlated with tumor burden. In different human cancers,
which exhibit considerable genetic heterogeneity, CTC numbers
are notoriously variable across different individuals and are
poorly correlated with radiographic measurements of tumor
burden (reviewed in Yu et al., 2011). However, longitudinal
follow-up of individual patients does show a correlation with
tumor response or progression. Such a trend is also evident in
the melanoma patients studied here, and it suggests that once
the detection platforms for human melanoma CTCs are opti-
mized, monitoring the number of these cells during therapy
may help guide treatment for metastatic cancer.
Althoughmost applications of CTC technologies have focused
on monitoring advanced cancers, the highly invasive nature of
cancer cells in this melanoma model made it possible to study
their generation in the setting of early, localized disease. Indeed,
in the mouse ear melanoma initiation model, we find that CTCs
are shed very early into the circulation, at a time when the pri-
mary lesion is defined by an increase in pigmentation preceding
the appearance of a tumor. Resection of the ear at this early
stage does not prevent the development of distant cutaneous
metastases, confirming the rapid blood-borne dissemination of
tumor cells. Remarkably, a relatively brief course of B-RAF inhib-
itor therapy is sufficient to suppress the development of distant
cutaneous metastases. Conceptually, these experiments lend
support to the use of anti-B-RAF therapies in the postoperative
adjuvant setting, where the relatively low tumor burden may
allow the drug to kill all residual disease and prevent recurrence
at distant sites. Two ongoing clinical trials (NCT01682083 and
NCT01667419) are currently testing this hypothesis. However,
identifying the subset of patients with stage II and III disease
who are at high risk of tumor recurrence following resection of
the primary lesion remains a major challenge, with histological
hallmarks such as tumor thickness, ulceration, and mitotic rate
enabling only incomplete patient stratification. Such patient
stratification is essential given B-RAF inhibitor-related toxicity
(Su et al., 2012). Optimization of human melanoma CTC-capture
platforms may allow detection of rare cells in patients with early
disease, potentially providing a predictivemeasure of recurrence
risk. In this context, it is of interest that the ability of primary
melanoma explants to generate CTCs following implantation
into immunodeficient mice appears to be predictive of their
recurrence risk (Quintana et al., 2012).
The gene-expression patterns correlated with melanoma
aggressiveness have not been well defined, possibly reflecting
the considerable heterogeneity in this disease (Schramm et al.,
Figure 4. Detection and Characterization of CTCs in Melanoma Patients
(A) Representative images of CTCs from patients with metastatic melanoma. CTCs are defined as being MEL+ and CD45. Upper: IF image of a MEL+CD45
melanoma CTC. Lower: bright-field (BF) image and merged image IF and BF of a CTC reveals intracellular ‘‘granules’’ marked with arrowheads. MEL, CSPG4/
MCAM/TYRP-1/aSMA antibody cocktail (upper) or CSPG4 (lower). Blue, DAPI; red, MEL. Scale bar, 10 mm.
(B) CTC counts of 174 samples from metastatic patients, 21 pretreatment samples, and 10 healthy donors. Median MEL(C/M/T/S)+/CD45 cell count is 8 cells/
2.5ml for all patient samples, 24 cells/2.5ml for pretreatment samples, and 1 cell/2.5ml for controls. Solid lines,median CTC counts; dashed line, threshold ofR3
cells/2.5 ml.
(C) CTCs display dynamic changes in patients and correlate with therapy responses. Blue curve, radiographic tumormeasurement; red curve, CTC counts. Br. M,
brain metastasis; SRS, stereotactic radiosurgery; Discont., treatment discontinued; B-RAFi/MEKi, dabrafenib/trametinib (patients M1, M3, and M4) or LGX818/
MEK163 (patient M2).
See also Figure S4 and Table S4.
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2012). In contrast, in the syngeneicmousemodel,wewereable to
identify a small set of markers that were consistently upregulated
in CTCs compared with either primary or metastatic tumors.
Although the initiating B-RAF mutation triggered the melanoma
model, CTCs demonstrated a further upregulation of B-RAF-
MAPK activity (Figure 3E, Delys thyroid). Consistent with a B-
RAF-MAPK-induced melanoma ‘‘dedifferentiation’’ phenotype
(Frederick et al., 2013), expression ofmanymelanocytic differen-
tiation genes, including MITF, GP100, andMelan-A, was consid-
erably lower inCTCs than in primary tumors (Figure S3G; X.L. and
D.A.H., unpublished data). Even the ‘‘melanosome’’ genes ex-
pressed by CTCs were mainly genes whose products involve
the maintenance of melanosome structures (e.g., ANXA2 and
LAMP1), rather than the classic melanocytic differentiation
genes (Table S2). The existence of melanoma stem cells
remains controversial (Quintana et al., 2008), and we did not
find any candidatemelanoma stem cell-specific genes, including
ABCB5 (Schatton et al., 2008), CD34, and CD271 (Boiko et al.,
2010; Held et al., 2010), to be enriched in CTCs. Interestingly,
we did note significantly increased expression levels of twomas-
ter transcription factors involving in stem cell reprogramming,
Klf4 and Myc, in the melanoma CTC populations (Table S3).
Canonical Wnt signaling has been shown to contribute to met-
astatic dissemination in the B-RAF/PTENmouse model (Damsky
et al., 2011), but themoststriking componentof theCTCsignature
identified herewas a similarity to a liver carcinomagene set linked
to noncanonical Wnt, TGF-b, and BMP signaling pathways (Fig-
ure 3E, Hoshida liver; Figures S3C–S3F; Hoshida et al., 2009).
That signaturealsoemerged inCTCsderived fromamousemodel
of pancreatic cancer, where it was correlated with anchorage
independent survival signals (Yu et al., 2012). This raises the
intriguing possibility that a set of conserved CTC-specific gene-
expression patterns may exist across different cancer types,
linked to signaling pathways that regulate cell survival by normally
adherent cells that travel in thebloodstream. Together, our results
indicate that the mouse melanoma CTC signature we identified
here is correlated with cellular invasiveness in human melanoma.
If this is confirmed in larger clinical trials, such a CTC-derived
expression signature may identify an aggressive subset of mela-
noma with a high risk of blood-borne metastatic spread and
help guide the rational treatment of early disease.
Although HBCTC-Chip has been shown to be effective for
capturing melanoma CTCs in the B-RAF/PTEN model, robust
platforms for studying human melanoma CTCs have proved
elusive, possibly due to the heterogeneity and phenotypic plas-
ticity of human melanomas (Hoek et al., 2008). We found that
weneeded to usea larger number of antibodies to reliably capture
human melanoma CTCs compared with mouse CTCs, which
resulted in increasednonspecificbindingbycontaminating leuko-
cytes and theneed toperformcomplex chip functionalizationpro-
tocols. As such, detailed molecular analysis of human melanoma
CTCs will require single-cell isolation protocols, as well as nontu-
mor epitope-drivenCTC isolation platforms (Ozkumur et al., 2013;
see Supplemental Discussion). Nonetheless, the human mela-
noma-specific HBCTC-Chip designed here allowed enumeration
of CTCs from patients with metastatic disease, with a dynamic
range that enabled longitudinal monitoring of treatment response
and disease progression. Indeed, within the parameters of652 Cell Reports 7, 645–653, May 8, 2014 ª2014 The Authorsperiodic sampling that was not timed to specific treatment
evaluations or therapeutic interventions, we observed a general
concordance between CTC numbers and clinical status in
patients undergoing B-RAF-targeted therapies for metastatic
melanoma. An unexpected finding in both human and mouse
melanoma CTCs was the presence of CTC clusters (Figures 1B
and S4F). Such groupings of CTCs in the circulation have been
observed in patients with various epithelial cancers (Cho et al.,
2012; Stott et al., 2010) and are likely a result of tumor fragments
breaking off into the circulation. Primary melanocytes exist as
single cells. As such, melanoma cells have not been thought to
formstrong intercellular adhesions; however, it was previously re-
ported that artificially generated melanoma microemboli display
increased tumorigenic potential compared with single melanoma
cells (Fidler, 1973). Therefore, the origin and functional signifi-
canceofmelanomaCTCclusters, and their contribution to human
melanoma metastasis, remain to be defined.
In summary, the analysis of melanoma CTCs in a well-defined
and homogeneous mouse model, together with emerging data
on humanmelanomaCTCs, is likely to provide important insights
into the biological drivers of blood-borne invasion in this disease.
The detection of CTCs in early invasive disease, as well as in
established metastatic cancer, may help guide the application
of increasingly powerful therapeutic regimens.
EXPERIMENTAL PROCEDURES
Detailed procedures and reagent information are provided in Supplemental
Experimental Procedures.
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